Blood-brain barrier transporters

Aschner M, Aschner JL. 1990. Mercury neurotoxicity mechanisms of blood-brain barrier transport. Neurosci Biobehav Rev 14 169-176. 

One should realize that the intracellular compartment as depicted in Figure 2 represents multiple cell types, whereas in vitro studies normally utilize a single cell type pertinent to characterizing specific attributes of drug transport in that cell system. The method of Shah et al. [51] would be of great benefit to investigating blood-brain barrier transport, consistent with a vascular-extravascular subcompartment brain model. 

Pardridge, W. M., Brain drug delivery and blood-brain barrier transport, Drug Deliv., 1996, 3, 99-115. 

Hasselbalch, S. G., Knudsen, G. M., Capaldo, B. etal. Blood-brain barrier transport and brain metabolism of glucose during acute hyperglycemia in humans. /. Clin. Endocrinol. Metab. 86 1986-1990, 2001. 

McCall, A. L., Millington, W. R. and Wurtman, R. J. 1982. Blood-brain barrier transport of caffeine Dose-related restriction of adenine transport. Life Science, 31 709-715. 

Figure 7. A serotonergic synapse including a depiction of the acute tryptophan depletion method discussed in the text. All large neutral amino acids (SLNAAs) share a common blood-brain barrier transporter. The serotonergic precursor, tryptophan, essentially competes with the other LNAAs for transport. Thus tryptophan is uniquely susceptible to acute dietary manipulation. Numerous serotonergic receptor types exist, including presynaptic S-HTm and (somatodendritic) 5-HTia autoreceptors and postsynaptic 5-HTia, 5-HTid, 5-HT2a 5-HT2c 5-HT3 and 5-HT4 receptors. Additional modulation of serotonin activity can occur via the action of selective serotonin re-uptake inhibitors (SSRls) including fluoxetine, fluvoxamine, and citalopram.

Terasaki, T., and A. Tsuji. 1994. Drug delivery to the brain utilizing blood-brain barrier transport systems. J Control Release 29 163. 

Wu, D., R. Boado, and W. Pardridge. 1996. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. J Pharmacol Exp Ther 276 206. 

Moriki, Y., et al. 2004. Involvement of P-glycoprotein in blood-brain barrier transport of pentazocine in rats using brain uptake index method. Biol Pharm Bull 27 932. 

Banks WA, Kastin AJ, Fasold MB. 1988. Differential effect of aluminum on the blood-brain barrier transport of peptides, technetium and albumin. J Pharmacol Exp Ther 244 579-585. 

Lee CG, Tang K, Cheung YB, et al. MDR1, the blood-brain barrier transporter, is associated with Parkinson s disease in ethnic Chinese. J Med Genet 2004 41(5) e60. 

Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998 70(5) 1781-1792. 

Delange ECM, Hesselink MB, Danhof M, Deboer AG, Breimer DD (1995) The use of intracerebral microdialysis to determine changes in blood-brain barrier transport characteristics. Pharm Res 12 129-133. 

Kumagai AK, Eisenberg IB, Pardridge WM (1987) Absoiptive-mediated endocytosis of cationized albumin and a beta-endoiphin-cationized albumin clrimeiic peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem 262 15214—15219. 

Banks WA, Farr SA, La Scola ME, Morley JE (2001) Intravenous human interleukin-la impairs memory processing in mice Dependence on blood-brain barrier transport into posterior division of the septum. J Pharmacol Exp Ther 299 536-541. 

Triguero D, Buciak JB, Yang J, Pardridge WM (1989) Blood-brain barrier transport of cationized immunoglobulin G Enhanced delivery compared to native protein. Proc Natl Acad Sci USA 86 4761 765. 

Deguchi Y, Miyakawa Y, Sakurada S, Naito Y, Motimoto K, Ohtsuki S, Hosoya K, Terasaki T (2003) Blood-brain barrier transport of a novel specific opioid peptide, H-Tyr-D-Arg-Phe-jS-Ala-OH (TAPA). J Neurochem 84 1154-1161... 

IN VITRO AND IN VIVO METHODS TO STUDY BLOOD-BRAIN BARRIER TRANSPORT... 

---